Alpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3408 for the Treatment of Melanoma
Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company's imaging agent, A9-3202, which entered the clinic last year Robert Meehan, M.D., appointed as Chief Medical Officer, bringing extensive clinical development expertise to advance the Company's radiotherapeutic pipeline Alpha-9 Oncology, a clinical-stageradiotherapeutic company developing targeted cancer therapies, today announced the […]